Goldman Sachs upgraded Beta Bionics (BBNX) to Buy from Neutral with a price target of $26, up from $18, which offers 31% upside. The firm’s analysis of the diabetes technology market shows sustained growth and profitability for Beta. The company should experience the most upside within the renewal segment of the market, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX: